New CANDID study explores cannabis therapy for IBD
Ed Hoffenberg, MD, and Edwin de Zoeten, MD are part of a new study supported by the Colorado Department of Public Health and Environment to evaluate the role of marijuana and its byproducts in the treatment of inflammatory bowel disease (IBD).
This search for new therapies will gain further momentum with the launch of a state-funded study on CANnabis anD Inflammatory Bowel Disease—or CANDID.
Nicknamed CANDID, the three-year Cannabis and Inflammatory Bowel Disease research seeks to clarify the benefits of cannabis in IBD treatment.
Treatment for inflammatory bowel disease at Children’s Colorado
Inflammatory bowel disease (IBD) has emerged as one of the most significant chronic conditions affecting the pediatric population. A causal force in malnutrition, growth failure, pubertal delay and more, IBD also impacts the psychosocial health of children and young adults at a critical point of development.
Children’s Colorado established the Pediatric Inflammatory Bowel Disease Center to integrate new IBD research and treatments as rapidly as possible. The multidisciplinary IBD center combines pediatric IBD specialists, nurses, dietitians, psychologists and social workers with a dedicated investigative team developing safe and more effective treatments.